22S1 Stock Chart & Stats
€4.46
--
Market closed
€4.46
--
Day’s Range― - ―
52-Week Range€4.46 - €5.19
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€2.45M
Enterprise Value-€3.16
Total Cash (Recent Filing)€3.92M
Total Debt (Recent Filing)€200.00K
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-132.69
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)4.58
Price to Sales (P/S)1.45
P/FCF Ratio-1.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-70.35
Revenue Forecast (FY)€8.66M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross-margin ExpansionImproving revenue alongside a substantial gross-margin gain indicates stronger commercial traction and better product economics. If sustained, the combination can increase contribution from each procedure, support reinvestment, and help narrow the gap between growth and eventual breakeven.
Pediatric Adoption And Hospital-account ExpansionBroad adoption across pediatric centers and a growing active hospital base strengthen Nuwellis’s clinical footprint and recurring consumables opportunity. Concentration in a defined growth segment can support utilization, reference-site credibility, and expansion of the broader cardiorenal platform.
Cardiorenal Platform ExpansionAdding kidney-function monitoring extends Nuwellis beyond fluid removal toward a more integrated cardiorenal offering. Broader clinical functionality may increase the value of its hospital relationships, create cross-selling opportunities, and improve differentiation as new products mature.
Bears Say
Severe Losses And Persistent Cash BurnPersistent operating and free-cash-flow deficits show that current revenue does not yet fund the business. Large operating losses require management to achieve meaningful scale or cost reductions, otherwise continued cash consumption can constrain investment and make financial stability dependent on outside funding.
Balance-sheet Stress And Limited LiquidityNegative equity reduces financial flexibility and signals that accumulated losses have weakened the capital structure. With modest cash relative to reported losses and expenses, Nuwellis has limited room to absorb execution setbacks, increasing pressure to improve cash generation or secure additional financing.
Reliance On Equity FinancingExternal equity funding helps extend operations but is not a substitute for internally generated cash flow. Repeated offerings and attached warrants can dilute existing holders and constrain financing flexibility, while unfavorable market access could make it harder to fund commercialization and product development.
Nuwellis News
22S1 FAQ
What was Nuwellis’s price range in the past 12 months?
Nuwellis lowest stock price was €4.46 and its highest was €5.19 in the past 12 months.
What is Nuwellis’s market cap?
Nuwellis’s market cap is €2.45M.
When is Nuwellis’s upcoming earnings report date?
Nuwellis’s upcoming earnings report date is Nov 17, 2026 which is in 69 days.
How were Nuwellis’s earnings last quarter?
Nuwellis released its earnings results on Aug 13, 2026. The company reported -€23.095 earnings per share for the quarter, missing the consensus estimate of -€20.633 by -€2.462.
Is Nuwellis overvalued?
According to Wall Street analysts Nuwellis’s price is currently Overvalued.
Does Nuwellis pay dividends?
Nuwellis does not currently pay dividends.
What is Nuwellis’s EPS estimate?
Nuwellis’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nuwellis have?
Currently, no data Available
What happened to Nuwellis’s price movement after its last earnings report?
Nuwellis reported an EPS of -€23.095 in its last earnings report, missing expectations of -€20.633. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Nuwellis?
Currently, no hedge funds are holding shares in DE:22S1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nuwellis
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
22S1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple positive operational and strategic developments (notably 26% revenue growth, a 70.1% gross margin, pediatric adoption, the RendiaTech acquisition, a new patent, leadership and board strengthening, and a ~$5M capital infusion). However, notable challenges remain: a ~$4.3M net loss, operating expenses up ~46%, modest cash on hand (~$2.2M), and a multi-quarter timeline to commercialize RendiaTech's target product. On balance, the highlights indicate meaningful early execution progress and strategic positioning, but the company must deliver on its burn reduction and commercialization milestones to sustain momentum.View all DE:22S1 earnings summariesTechnical Analysis
Aethlon Medical
―
PAVmed
―
Catheter Precision
―
Bone Biologics
―
Heart Test Laboratories, Inc.
―